BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28515094)

  • 1. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
    Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
    Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
    Power J; Poole KE; van Bezooijen R; Doube M; Caballero-Alías AM; Lowik C; Papapoulos S; Reeve J; Loveridge N
    J Bone Miner Res; 2010 Aug; 25(8):1867-76. PubMed ID: 20200987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody.
    Morrell AE; Robinson ST; Ke HZ; Holdsworth G; Guo XE
    Bone; 2021 Aug; 149():115967. PubMed ID: 33892178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model.
    Morse A; McDonald MM; Schindeler A; Peacock L; Mikulec K; Cheng TL; Liu M; Ke HZ; Little DG
    Calcif Tissue Int; 2017 Aug; 101(2):217-228. PubMed ID: 28391431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.
    Hadaya D; Gkouveris I; Soundia A; Bezouglaia O; Boyce RW; Stolina M; Dwyer D; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2019 Jan; 34(1):171-181. PubMed ID: 30184271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.